[go: up one dir, main page]

UA114699C2 - A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system - Google Patents

A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system

Info

Publication number
UA114699C2
UA114699C2 UAA201300107A UAA201300107A UA114699C2 UA 114699 C2 UA114699 C2 UA 114699C2 UA A201300107 A UAA201300107 A UA A201300107A UA A201300107 A UAA201300107 A UA A201300107A UA 114699 C2 UA114699 C2 UA 114699C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
methods
conditions associated
treating diseases
cardiovascular system
Prior art date
Application number
UAA201300107A
Other languages
Ukrainian (uk)
Inventor
Олєг Ільіч Епштейн
Свєтлана Алєксандровна Сєргєєва
Людміла Фьодоровна Долгових
Владімір Івановіч Пєтров
Original Assignee
Олєг Ільіч Епштейн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129291/15A external-priority patent/RU2525156C2/en
Priority claimed from RU2010129292/15A external-priority patent/RU2523557C2/en
Priority claimed from RU2010129290/15A external-priority patent/RU2525155C2/en
Priority claimed from RU2011110106/15A external-priority patent/RU2523451C2/en
Application filed by Олєг Ільіч Епштейн filed Critical Олєг Ільіч Епштейн
Publication of UA114699C2 publication Critical patent/UA114699C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Винахід представляє фармацевтичну композицію, яка застосовується пацієнтами, що страждають принаймні від одного із симптомів серцево-судинного захворювання, а вказана композиція складається з а) активованої потенційованої форми антитіла до АТ1 рецептора ангіотензину II та б) активованої потенційованої форми антитіла до ендотеліальної NO-синтази.The invention is a pharmaceutical composition for use in patients suffering from at least one of the symptoms of cardiovascular disease, and the composition consists of a) activated potentiated antibody to the AT1 receptor angiotensin II and b) activated potentiated antibody form to the endothelial antibody.

UAA201300107A 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system UA114699C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010129291/15A RU2525156C2 (en) 2010-07-15 2010-07-15 Method of treatment and prevention of arterial hypertension and pharmaceutical composition for treatment of arterial hypertension
RU2010129292/15A RU2523557C2 (en) 2010-07-15 2010-07-15 Method of treating vegetovascular dystonia and pharmaceutical composition for treating vegetovascular dystonia
RU2010129290/15A RU2525155C2 (en) 2010-07-15 2010-07-15 Method of treating chronic heart failure and pharmaceutical composition for complex therapy of chronic heart failure
RU2011110106/15A RU2523451C2 (en) 2011-03-17 2011-03-17 Method of treating chronic cardiac failure and pharmaceutical composition for treating chronic cardiac failure
PCT/IB2011/002391 WO2012007846A2 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system

Publications (1)

Publication Number Publication Date
UA114699C2 true UA114699C2 (en) 2017-07-25

Family

ID=44899163

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201300107A UA114699C2 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system

Country Status (23)

Country Link
US (1) US8703124B2 (en)
EP (1) EP2593482A2 (en)
JP (1) JP2013532183A (en)
KR (1) KR20140009110A (en)
AR (1) AR084707A1 (en)
AU (1) AU2011278039B2 (en)
BR (1) BR112013000779A2 (en)
CA (1) CA2804969A1 (en)
DE (1) DE112011102356T5 (en)
DK (1) DK201370080A (en)
EA (1) EA201300128A1 (en)
EE (1) EE201300004A (en)
FI (1) FI20135145A7 (en)
FR (1) FR2962654A1 (en)
GB (1) GB2496795A (en)
IT (1) ITTO20110640A1 (en)
MX (1) MX2013000544A (en)
NO (1) NO20130217A1 (en)
PH (1) PH12013500111A1 (en)
SE (1) SE1350177A1 (en)
SG (1) SG187034A1 (en)
UA (1) UA114699C2 (en)
WO (1) WO2012007846A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (en) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
RU2201255C1 (en) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Medicinal agent and method of regulation of vascular tonus
RU2309732C1 (en) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation
MX2013000543A (en) * 2010-07-15 2013-10-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
FR2962652A1 (en) 2010-07-15 2012-01-20 Oleg Iliich Epshtein PHARMACEUTICAL ASSOCIATION COMPOSITION AND ITS USE IN METHODS FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
RU2013111961A (en) 2013-03-18 2014-09-27 Олег Ильич Эпштейн METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER
RU2013111962A (en) 2013-03-18 2014-09-27 Олег Ильич Эпштейн METHOD FOR DETERMINING THE EXPRESSION OF MODIFICATION ACTIVITY ASSOCIATED WITH A CARRIER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2181297C2 (en) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
RU2201255C1 (en) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Medicinal agent and method of regulation of vascular tonus
UA76641C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medicinal agent and method for curing diseases of prostate
UA76639C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medication and method for treating erectile dysfunctions
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
JP5239899B2 (en) 2008-07-29 2013-07-17 株式会社リコー Image forming apparatus

Also Published As

Publication number Publication date
WO2012007846A2 (en) 2012-01-19
DK201370080A (en) 2013-02-14
AU2011278039A1 (en) 2013-03-07
EA201300128A1 (en) 2013-12-30
GB201302656D0 (en) 2013-04-03
FI20135145L (en) 2013-02-15
KR20140009110A (en) 2014-01-22
US20120251584A1 (en) 2012-10-04
EE201300004A (en) 2013-08-15
WO2012007846A3 (en) 2012-04-12
ITTO20110640A1 (en) 2012-01-16
DE112011102356T5 (en) 2013-04-18
AU2011278039B2 (en) 2015-07-23
EP2593482A2 (en) 2013-05-22
US8703124B2 (en) 2014-04-22
SG187034A1 (en) 2013-02-28
FR2962654A1 (en) 2012-01-20
JP2013532183A (en) 2013-08-15
SE1350177A1 (en) 2013-04-12
CA2804969A1 (en) 2012-01-19
GB2496795A (en) 2013-05-22
FI20135145A7 (en) 2013-02-15
PH12013500111A1 (en) 2017-07-26
AR084707A1 (en) 2013-06-05
MX2013000544A (en) 2013-10-28
NO20130217A1 (en) 2013-03-22
BR112013000779A2 (en) 2016-06-07

Similar Documents

Publication Publication Date Title
UA114699C2 (en) A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
CY1124307T1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF
EA201291336A1 (en) SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINE AND THEIR APPLICATION
EA201390060A1 (en) ANNELED PYRIMIDINES AND TRIAZINES AND THEIR APPLICATION FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
CY1119852T1 (en) ANTIBODY PACKAGING AND THERAPEUTICS
CY1123051T1 (en) TAPENTADOL FOR THE PREVENTION AND TREATMENT OF DEPRESSION AND ANXIETY
MA34091B1 (en) Antibody antibody cd40
UA109271C2 (en) COMBINATION OF PHYTOCANABINOIDS AND THEMOSOLAMIDE FOR THE TREATMENT OF GLIOMA
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
EA201491009A1 (en) PLATINOUS LIZATE GEL
JO3462B1 (en) Human Antibodies to GFR?3 and methods of use thereof
EP2683382A4 (en) DOSAGE REGIMES FOR THE TREATMENT OF FABRY'S DISEASE
EA201290964A1 (en) Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
MX2011012691A (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
BR112013002167A2 (en) bispecific antibody, pharmaceutical composition, use, method of treatment of a cancer patient and a patient suffering from inflammation
UA109650C2 (en) BIS-ARLYZED ARILTRIAZOLONS AND THEIR APPLICATIONS
EA201390506A1 (en) POLYPEPTIDES THAT BIND THE COMPONENT C5 OF THE HUMAN COMPLEX
EA201270815A1 (en) ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
EP2429993A4 (en) INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
EP2398459A4 (en) TRANSDERMAL ADMINISTRATION OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE
RU2018145985A (en) ACTIVIN-ACTRII ANTAGONISTS AND THEIR APPLICATION FOR TREATMENT OF BONE TISSUE DISORDERS AND OTHER DISORDERS
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
GB2496794A (en) Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract
EE05761B1 (en) Combined pharmaceutical composition for the treatment of diabetes and metabolic disorders
FI20135146A7 (en) Pharmaceutical compositions and methods of treatment